Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-18
2011-01-18
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S373000, C514S236800, C514S342000, C514S301000, C514S312000, C544S133000, C546S153000, C546S271100, C548S212000, C548S206000, C548S214000
Reexamination Certificate
active
07872033
ABSTRACT:
The present application relates to isothiazolylidene containing compounds of Formula (I)wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
REFERENCES:
patent: 1820504 (2007-08-01), None
patent: 9531448 (1995-11-01), None
patent: 0063207 (2000-10-01), None
patent: 0155139 (2001-08-01), None
patent: 0155140 (2001-08-01), None
patent: WO-2004110453 (2004-12-01), None
patent: WO-2006051704 (2006-05-01), None
Smith, D. A. Current Opinion in Drug Discovery & Development 2007, 10, 550-559.
Testa, B. Current Opinion in Chemical Biology 2009, 13, pp. 338-344.
Wang et al. Drug Delivery: Principles and Applications, 2005 John Wiley & Sons, Inc. Publication, Section 8.3, pp. 136-137.
Rautio et al. Nature Reviews Drug Discovery 2008, 7, pp. 255-270.
International Search Report for application No. PCT/US08/060400, Mailed on Oct. 17, 2008, 3 pages.
Arevalo-Martin, et al., Journal of Neuroscience vol. 23, No. 7 (2003), pp. 2511-2516.
Benito, et al., Journal of Neuroscience, vol. 23 No. 35 (2003), pp. 11136-11141.
Berge, et al., Journal of Pharmaceutical Sciences, vol. 66 (1977), pp. 1 et seq.
Bouchard, et al. Life Science, vol. 72 (2003), pp. 1859-1870.
Boyle, et al., Nature, vol. 423 (2003) pp. 337-342.
Brennan, et al., Pain, vol. 64 (1996) pp. 493.
Buckley, et al., European Journal of Pharacology, vol. 396 (2000), pp. 141-149.
Carlisle, et al., Interational Immunopharmacology, vol. 2 (2002), pp. 69.
Carrier, et al., Current Drug Targets—CNS & Neurological Disorders, vol. 4 (2005), pp. 657-665.
Casanova, et al., Journal of Clinical Investigation, vol. 111 (2003), pp. 43-50.
Chaplan, et al., Journal of Neuroscience Methods, vol. 53 (1994), pp. 55.
Cichewicz, Life Science, vol. 74 (2004), pp. 1317-1324.
Clayton, et al., Pain, 2002, 96, 253-260.
Dixon, Ann. Rev. Pharmacol. Toxicology, vol. 20 (1980), pp. 441.
Filippo, et al., Journal of Leukocyte Biology, vol. 75 (2004), pp. 453-459.
Galiegue, et al., European Journal of Biochemistry, vol. 232 (1995), pp. 54-61.
Goerdeler, et al., Chemische Berichte, vol. 102 (1969), pp. 2273-2284.
Grotenhermen, et al., Expert Opinion on Pharmacotherapy, vol. 4, No. 12 (2003), pp. 2367-2371.
Hanus, et al., Proceedings of the National Academy of Science, vol. 96 (1996), pp. 14228-14233.
Hohmann, et al., Journal of Pharmacology and Experimental Therapeutics, vol. 308 (2004), pp. 446-453.
Ibrahim, M. M., et al., Proceedings of the National Academy of Science, vol. 100 (2003), pp. 10529-10533.
Ibrahim, M. M., et al., Proceedings of the National Academy of Science, vol. 102, No. 8 (2005), pp. 3093-3098.
Ihenetu, et al., European Journal of Pharacology, vol. 458 (2003), pp. 207-215.
Julien, et al., Gastroenterology, vol. 128 (2005), pp. 742-755.
Karsak, et al., Human Molecular Genetics, vol. 14, No. 22(2005), pp. 3389-3396.
Kim, et al., Pain, vol. 50 (1992), pp. 355.
Lepicier, et al., British Journal of Pharmacology, vol. 139 (2003), pp. 805-815.
Linn, et al., Journal of American Chemistry Society, vol. 85 (1963), pp. 2032.
Lotersztajn, et al., Annual Review of Pharmacology and Toxicology, 2005, 45, 605-628.
Malan, et al., Pain, vol. 93 (2001), pp. 239-245.
Maresz, et al., Journal of Neurochemsitry, vol. 95 (2005), pp. 437-445.
Mathison, et al., British Journal of Pharmacology, vol. 142 (2004), pp. 1247-1254.
McKallip, et al., Blood, vol. 15, No. 2 (2002), pp. 637-634.
Nackley, et al., Neuroscience, vol. 119 (2003), pp. 747-757.
Ni, et al., Multiple Sclerosis, vol. 10 (2004), pp. 158-164.
Patel, et al., British Journal of Pharmacology, 140 (2003), pp. 261-268.
Pertwee, Pharmacology Theroy, vol. 95 (2002), pp. 165-174.
Prescott, Ed., Methods in Cell Biology, vol. XIV, (New York, Academic Press, 1976), p. 33 et seq.
Quartilho, et al., Anesthesiology, vol. 99 (2003), pp. 955-960.
Ralston, et al., Nature Medicine, vol. 11 (2005), pp. 774-779.
Ramirez, et al., Journal of Neurosciene, vol. 25, No. 8 (2005), pp. 1904-1913.
Sanchez, et al., Cancer Research, vol. 61 (2001), pp. 5784-5789.
Steffens, et al., Nature, vol. 434 (2005), pp. 782-786.
Valenzano, K. J., et al., Neuropharmacology, vol. 48 (2005), pp. 658-672.
Warhurst, et al., Gut, vol. 42 (1998), pp. 208-213.
Wright, et al., Gastroenterology, vol. 129 (2005), pp. 437-453.
Yoshihara, et al., Allergy and Immunology, vol. 138 (2005), pp. 80-87.
Yoshihara, et al., American Journal of Respiratory and Critical Care Medicine, vol. 170 (2004), pp. 941-946.
Yoshihara, et al., Journal of Pharmacological Sciences, vol. 98, No. 1 (2005), pp. 77-82.
Carroll William A.
Dart Michael J.
Kolasa Teodozyj
Li Tongmei
Nelson Derek W.
Abbott Laboratories
Anderson Rebecca L
Coughlin Matthew P
Parial Andrew M.
LandOfFree
Compounds as cannabinoid receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds as cannabinoid receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as cannabinoid receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2650201